down arrow

Sinopep-Allsino Bio Pharmaceutical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000051X5
CNY
39.07
0.52 (1.35%)

Dec 19

SHG

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Sinopep-Allsino Bio Pharmaceutical Co., Ltd.
Why is Sinopep-Allsino Bio Pharmaceutical Co., Ltd. ?
1
Negative results in Mar 25
  • DEBT-EQUITY RATIO (HY) Highest at 46.92 %
  • INTEREST(Q) Highest at CNY 12.89 MM
2
With ROE of 15.91%, it has a expensive valuation with a 4.39 Price to Book Value
  • Over the past year, while the stock has generated a return of 3.33%, its profits have risen by 31.9%
3
Underperformed the market in the last 1 year
  • The stock has generated a return of 3.33% in the last 1 year, much lower than market (China Shanghai Composite) returns of 15.14%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sinopep-Allsino Bio Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Sinopep-Allsino Bio Pharmaceutical Co., Ltd.
5.72%
-0.66
51.08%
China Shanghai Composite
14.61%
1.04
14.52%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
45.37%
EBIT Growth (5y)
116.86%
EBIT to Interest (avg)
12.15
Debt to EBITDA (avg)
0.69
Net Debt to Equity (avg)
0.45
Sales to Capital Employed (avg)
0.36
Tax Ratio
9.76%
Dividend Payout Ratio
34.19%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.26%
ROE (avg)
9.49%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
4.39
EV to EBIT
26.94
EV to EBITDA
18.14
EV to Capital Employed
3.23
EV to Sales
7.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
11.98%
ROE (Latest)
15.91%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 468.55 MM

ROCE(HY)

Highest at 19.36%

PRE-TAX PROFIT(Q)

At CNY 177.34 MM has Grown at 120.44%

NET PROFIT(Q)

At CNY 152.62 MM has Grown at 130.1%

RAW MATERIAL COST(Y)

Fallen by -13.27% (YoY

NET SALES(Q)

Highest at CNY 562.52 MM

-16What is not working for the Company
DEBT-EQUITY RATIO (HY)

Highest at 46.92 %

INTEREST(Q)

Highest at CNY 12.89 MM

Here's what is working for Sinopep-Allsino Bio Pharmaceutical Co., Ltd.
Operating Cash Flow
Highest at CNY 468.55 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales
At CNY 562.52 MM has Grown at 58.41%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (CNY MM)

Pre-Tax Profit
At CNY 177.34 MM has Grown at 120.44%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit
At CNY 152.62 MM has Grown at 130.1%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (CNY MM)

Net Sales
Highest at CNY 562.52 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

Raw Material Cost
Fallen by -13.27% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sinopep-Allsino Bio Pharmaceutical Co., Ltd.
Interest
At CNY 12.89 MM has Grown at 10.59%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio
Highest at 46.92 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Interest
Highest at CNY 12.89 MM
in the last five periods and Increased by 10.59% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."